PFIZER CEO ANTICIPATES DOUBLE-DIGIT GROWTH FOR NEWLY LAUNCHED PRODUCTS THIS YEAR - TD COWEN CONFERENCE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 21 hours ago
0mins
Should l Buy PFE?
Source: moomoo
- CEO's Expectations: Pfizer's CEO anticipates that newly launched products will continue to grow significantly this year.
- Growth Projection: The company expects to achieve double-digit growth in its product offerings.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFE
Wall Street analysts forecast PFE stock price to rise
16 Analyst Rating
5 Buy
11 Hold
0 Sell
Moderate Buy
Current: 27.650
Low
24.00
Averages
28.56
High
35.00
Current: 27.650
Low
24.00
Averages
28.56
High
35.00
About PFE
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reasons to Invest in Pfizer Stock
- Market Performance Analysis: Pfizer's market capitalization stands at $154 billion, and despite an average annual loss of 8.8% over the past three years, the stock has risen 10.4% year-to-date, indicating some market recovery potential.
- Dividend Attraction: With a dividend yield of 6.4%, Pfizer's steady payment of 349 consecutive dividends, despite a modest average annual growth of 3% over the past five years, underscores the company's financial stability.
- R&D Investment Outlook: Pfizer invested $10.4 billion in research and development in 2025, actively developing 102 drug candidates, with 32 in late-stage Phase 3, showcasing significant future growth potential.
- Operational Growth Situation: The company's recent fourth-quarter results showed a 3% year-over-year revenue decline, but operational growth reached 9% when excluding the impacts of COVID-19 vaccine and Paxlovid, indicating resilience in its core business.
See More
PFIZER CEO CLAIMS FDA CBER DIRECTOR IS IGNORING STAFF RECOMMENDATIONS - TD COWEN CONFERENCE
Pfizer CEO's Statement: The CEO of Pfizer has criticized the current director of the FDA, stating that he is not adhering to the recommendations provided by his staff.
Concerns Over FDA Leadership: This statement raises concerns about the leadership and decision-making processes within the FDA, particularly regarding drug approvals and public health policies.
See More
Priovant Secures FDA Priority Review for Brepocitinib
- FDA Priority Review: Priovant Therapeutics announced that its drug brepocitinib for dermatomyositis has received priority review from the FDA, marking a significant advancement in the treatment of rare diseases and potentially accelerating the drug's market entry.
- Clinical Trial Results: The New Drug Application is supported by data from the Phase 3 VALOR study involving 241 patients, where brepocitinib at a 30 mg dose demonstrated statistically significant improvement in the myositis Total Improvement Score, achieving the study's primary endpoint and enhancing the likelihood of FDA approval.
- Market Potential: If approved, brepocitinib will be the first FDA-approved targeted therapy for dermatomyositis, expected to fill a market gap and meet the urgent need for effective treatments, thereby enhancing Priovant's market position.
- Company Commitment: Priovant CEO Ben Zimmer stated that the company is committed to working closely with the FDA to expedite the drug's availability, reflecting its strong focus on patient welfare and proactive engagement with market opportunities.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
PFIZER CEO ANNOUNCES COMPANY WILL LEAD IN TESTING ADVANCED STRATEGIES TO OPTIMIZE OBESITY PORTFOLIO - TD COWEN CONFERENCE
CEO's Statement: The CEO of Pfizer emphasized the company's commitment to being at the forefront of testing the most aggressive forms of treatments.
Focus on Maximization: The CEO highlighted the goal of maximizing the potential of their portfolio, particularly in the context of obesity treatments.
See More
Reasons to Invest in Pfizer Stock
- Market Performance Analysis: Pfizer's market capitalization stands at $154 billion, and despite an average annual loss of 8.8% over the past three years, the stock has risen 10.4% year-to-date, indicating some market recovery potential.
- Dividend Attraction: With a dividend yield of 6.4%, Pfizer's steady payment of 349 consecutive dividends, despite a modest average annual growth of 3% over the past five years, underscores the company's financial stability.
- R&D Investment Outlook: Pfizer invested $10.4 billion in research and development in 2025, actively developing 102 drug candidates, with 32 in late-stage Phase 3, showcasing significant future growth potential.
- Operational Growth Situation: The company's recent fourth-quarter results showed a 3% year-over-year revenue decline, but operational growth reached 9% when excluding the impacts of COVID-19 vaccine and Paxlovid, indicating resilience in its core business.
See More
PFIZER CEO CLAIMS FDA CBER DIRECTOR IS IGNORING STAFF RECOMMENDATIONS - TD COWEN CONFERENCE
Pfizer CEO's Statement: The CEO of Pfizer has criticized the current director of the FDA, stating that he is not adhering to the recommendations provided by his staff.
Concerns Over FDA Leadership: This statement raises concerns about the leadership and decision-making processes within the FDA, particularly regarding drug approvals and public health policies.
See More
Priovant Secures FDA Priority Review for Brepocitinib
- FDA Priority Review: Priovant Therapeutics announced that its drug brepocitinib for dermatomyositis has received priority review from the FDA, marking a significant advancement in the treatment of rare diseases and potentially accelerating the drug's market entry.
- Clinical Trial Results: The New Drug Application is supported by data from the Phase 3 VALOR study involving 241 patients, where brepocitinib at a 30 mg dose demonstrated statistically significant improvement in the myositis Total Improvement Score, achieving the study's primary endpoint and enhancing the likelihood of FDA approval.
- Market Potential: If approved, brepocitinib will be the first FDA-approved targeted therapy for dermatomyositis, expected to fill a market gap and meet the urgent need for effective treatments, thereby enhancing Priovant's market position.
- Company Commitment: Priovant CEO Ben Zimmer stated that the company is committed to working closely with the FDA to expedite the drug's availability, reflecting its strong focus on patient welfare and proactive engagement with market opportunities.
See More
Analysis of Growth Drivers in the Biliary Tract Cancer Market
- Market Size Growth: The biliary tract cancer market is projected to reach $1.1 billion in 2024, with the U.S. accounting for approximately 60% of this market, indicating a strong demand for new therapies in this leading region.
- Emerging Drug Launches: The introduction of new drugs such as Tinengotinib and Rilvegostomig is expected to further drive market growth, particularly in the areas of targeted therapies and immuno-oncology, enhancing treatment options for patients.
- Advancements in Diagnostic Technology: Improvements in imaging techniques like MRI, endoscopic ultrasound, and PET have enhanced the accuracy of biliary tract cancer diagnoses, enabling earlier detection and personalized treatment approaches, thereby improving patient outcomes.
- Market Dynamics in Treatment: By 2034, chemotherapy is expected to remain the primary revenue source for biliary tract cancer treatment, and the introduction of new therapies will alter the competitive landscape, fostering medical innovation and economic growth.
See More
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.
Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.
Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.
Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.
See More
PFIZER CEO ANNOUNCES COMPANY WILL LEAD IN TESTING ADVANCED STRATEGIES TO OPTIMIZE OBESITY PORTFOLIO - TD COWEN CONFERENCE
CEO's Statement: The CEO of Pfizer emphasized the company's commitment to being at the forefront of testing the most aggressive forms of treatments.
Focus on Maximization: The CEO highlighted the goal of maximizing the potential of their portfolio, particularly in the context of obesity treatments.
See More
